LAP3 and Hypoglycemia: Linagliptin and other DPP-4 inhibitors suppress DPP-4, a peptidase which cleaves hypoglycemia incretins secreted by intestinal L cells such as glucagon-like peptide (GLP)-1, thereby lowering the post-prandial blood glucose level [19,20].